The Science of SLD and Dysmetabolism-The Role of Metabolic Dysfunction and Alcohol in Steatohepatitis

Video Transcription

Video Summary

The talk explains MET-ALD as the clinical syndrome caused by synergy between metabolic dysfunction and at least moderate alcohol intake, and notes it may account for ~39% of advanced liver disease. Risk of advanced disease rises markedly in drinkers with metabolic risk factors. Pathogenesis begins in the gut: obesogenic nutrients and alcohol damage the intestinal barrier, thin mucus, and drive dysbiosis, allowing bacterial products (e.g., LPS) into portal blood. In the liver this triggers lipogenesis, inflammasome and Kupffer cell activation, TNF-α signaling, stellate cell activation, inflammation, and fibrosis—often before classic histology shows “steatohepatitis.” Steatosis reflects disrupted lipid droplet biology; ultrastructural studies show sinusoidal capillarization, compression by lipid droplets, leukocyte trapping, and even lipid droplets escaping into sinusoids causing obstruction. Organoid and mouse models show combined diet plus alcohol worsens steatosis and injury and downregulates bile acid, xenobiotic, and alcohol-metabolizing pathways, potentially increasing vulnerability. The speaker argues MET-ALD is systemic (metabolic, cardiovascular, renal, cancer risks) and needs earlier detection, destigmatized care, lifestyle and AUD treatment, and aggressive management of insulin resistance and dyslipidemia.

Keywords

MET-ALD

metabolic dysfunction and alcohol synergy

gut barrier dysfunction and dysbiosis

LPS-driven hepatic inflammation and fibrosis

steatosis lipid droplet biology and sinusoidal capillarization